JP MORGAN/CALL/REGENERON PHARMACEUTICALS/1070/0.01/16.08.24 Share Price

Warrant

DE000JB7W5B7

Real-time Bid/Ask 06:35:13 05/07/2024 pm IST
0.19 EUR / 0.22 EUR +7.89% Intraday chart for JP MORGAN/CALL/REGENERON PHARMACEUTICALS/1070/0.01/16.08.24
Current month-32.14%
1 month+46.15%
Date Price Change
05/24/05 0.19 0.00%
04/24/04 0.19 -32.14%
03/24/03 0.28 +27.27%
02/24/02 0.22 -24.14%
01/24/01 0.29 +3.57%

Delayed Quote Börse Stuttgart

Last update July 05, 2024 at 04:31 pm IST

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying REGENERON PHARMACEUTICALS, INC.
Issuer J.P. Morgan
WKN JB7W5B
ISINDE000JB7W5B7
Date issued 18/12/2023
Strike 1,070 $
Maturity 16/08/2024 (42 Days)
Parity 100 : 1
Emission price 0.24
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.44
Lowest since issue 0.08
Spread 0.03
Spread %13.64%

Company Profile

Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from product sales (56.6%); - revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%); - other (3%): primarily revenues from sales of technology licenses and subcontracted research services. At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
Sector
-
More about the company

Ratings for Regeneron Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: Regeneron Pharmaceuticals, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,024 USD
Average target price
1,051 USD
Spread / Average Target
+2.67%
Consensus